Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00075608 · OUTCOME

Feasibility and Tolerability

2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis · Source last updated 2017-01-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
Not reported
Unit
Not reported
Interval / dispersion
Not reported
Time frame
3 months after treatment and annually

What was measured

Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events

Analysis population: No data were collected or analyzed due to study termination

Groups in this outcome

Second Transplant

Participants underwent a second treatment with high dose chemotherapy and stem cell transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Second Transplant0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields
denoms
  1. counts
    1. group Id
      OG000
      value
      0
    units
    Participants
description
Feasibility and tolerability will be evaluated based on participants completing second transplant with tolerable adverse events
groups
  1. description
    Participants underwent a second treatment with high dose chemotherapy and stem cell transplant
    id
    OG000
    title
    Second Transplant
population Description
No data were collected or analyzed due to study termination
reporting Status
POSTED
time Frame
3 months after treatment and annually
title
Feasibility and Tolerability
type
PRIMARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice